menu ☰
menu ˟

ATTR-ACT: Tafamidis improves quality of life in transthyretin amyloid cardiomyopathy

14 Sep 2019
PHILADELPHIA — Tafamidis was associated with improvements in a variety of metrics of quality of life in patients with transthyretin amyloid cardiomyopathy, according to a new analysis from the ATTR-ACT trial.As Healio previously reported, in the ma...

Click here to view the full article which appeared in Cardiology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.